References

References

  1. NeuroStar Prescribing Information.
  2. World Health Organization. Depression fact sheet No.369. http://www.who.int/mediacentre/factsheets/fs369/en/index.html. Accessed February 27, 2013.
  3. World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Accessed March 12, 2013.
  4. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press (2008).
  5. Janicak PG, et al. (2008). Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry, 69(2):222-232.
  6. Data on file. Neuronetics, Inc.
  7. O’Reardon JP, et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry, 62(11):1208-1216.
  8. George MS, et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry, 67(5):507-516.
  9. Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite naturalistc, observational study of acute treatment outcomes in clinical practice. Depress Anxiety, 29(7):587-596.
  10. Avery DH, et al. (2008). Transcranial Magnetic Stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry, 69(3):441-451.
  11. McDonald WM, et al. (2011). Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety, 28(11):973-980.
  12. Janicak PG, et al. (2010). Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation, 3(4):187-199.
  13. Demitrack MA, Thase ME. (2009). Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull, 42(2):5-38.
  14. Liston C, et al. (2014) Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol. Psychiatry 76(7): 517–526
  15. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. www.who.int/whr/2001/en/whr01_en.pdf. Accessed March 12, 2013.
  16. Kessler, RC et al. (2003). Epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-3105.
  17. World Health Organization. The ICD-10 classifications of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. www.who.int/classifications/icd/en/bluebook.pdf. Accessed March 12, 2013.
  18. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.
  19. Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180.
  20. Dunner DL, et al. (2014) A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.
  21. Mantovani A, et al. (2012). Long-Term Efficacy of Repeated Daily Prefrontal Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression. Depress Anxiety, 29 (10):883-890.

1. NeuroStar Prescribing Information.

2. World Health Organization. Depression fact sheet No.369. LINK. Accessed February 27, 2013.

3. World Health Organization. The global burden of disease: 2004 update. LINK. Accessed March 12, 2013.

4. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press (2008).

5. Janicak PG, et al. (2008). Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry, 69(2):222-232.

6. Data on file. Neuronetics, Inc.

7. O’Reardon JP, et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry, 62(11):1208-1216.

8. George MS, et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry, 67(5):507-516.

9. Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite naturalistc, observational study of acute treatment outcomes in clinical practice. Depress Anxiety, 29(7):587-596.

10. Avery DH, et al. (2008). Transcranial Magnetic Stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry, 69(3):441-451.

11. McDonald WM, et al. (2011). Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety, 28(11):973-980.

12. Janicak PG, et al. (2010). Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation, 3(4):187-199.

13. Demitrack MA, Thase ME. (2009). Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull, 42(2):5-38.

14. Liston C, et al. (2014) Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol. Psychiatry 76(7): 517–526

15. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. LINK. Accessed March 12, 2013.

16. Kessler, RC et al. (2003). Epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-3105.

17. World Health Organization. The ICD-10 classifications of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. LINK. Accessed March 12, 2013.

18. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.

19. Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180.

20. Dunner DL, et al. (2014) A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.

21. Mantovani A, et al. (2012). Long-Term Efficacy of Repeated Daily Prefrontal Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression. Depress Anxiety, 29 (10):883-890.